Skip to main
IMVT

Immunovant Inc (IMVT) Stock Forecast & Price Target

Immunovant Inc (IMVT) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 14%
Hold 43%
Sell 0%
Strong Sell 0%

Bulls say

Immunovant Inc. demonstrates a promising outlook based on its innovative focus on IMVT-1402, an FcRn inhibitor that has shown significant disease-modifying potential in autoimmune diseases like Graves' disease (GD). The reported 81% responder rate during a six-month off-treatment period, comparable to the 70%-80% rate seen during active treatment, indicates the treatment's durability and effectiveness, even among patients unresponsive to traditional therapies. Additionally, the consistent reduction in thyroid-stimulating hormone receptor autoantibodies (TRAb) further supports the therapeutic potential of FcRn blockers, enhancing investor confidence in the company's growth prospects.

Bears say

Immunovant Inc operates as a clinical-stage immunology company focused on developing treatments for autoimmune diseases, notably through its investigational drug IMVT-1402. A concerning aspect of Immunovant's outlook is the association of persistently high TRabs with elevated rates of relapse, signaling potential challenges in clinical efficacy and patient outcomes. Furthermore, the complications arising from TRAbs-mediated TSHR activation, including inflammation and the risk of optic nerve compression, may hinder the therapeutic potential of its product candidates and contribute to overall investor uncertainty.

Immunovant Inc (IMVT) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 14% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunovant Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunovant Inc (IMVT) Forecast

Analysts have given Immunovant Inc (IMVT) a Buy based on their latest research and market trends.

According to 7 analysts, Immunovant Inc (IMVT) has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunovant Inc (IMVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.